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AbstrACt
Objective To explore the perspectives of general 
practitioners (GPs) concerning the risk of opioid misuse 
in people with cancer and pain and related clinical 
considerations.
Design A qualitative approach using semistructured 
telephone interviews. Analysis used an integrative 
approach.
setting Primary care.
Participants Australian GPs with experience of 
prescribing opioids for people with cancer and pain.
results Twenty- two GPs participated, and three themes 
emerged. Theme 1 (Misuse is not the main problem) 
contextualised misuse as a relatively minor concern 
compared with pain control and toxicity, and highlighted 
underlying systemic factors, including limitations in 
continuity of care and doctor expertise. Theme 2 (‘A 
different mindset’ for cancer pain) captured participants’ 
relative comfort in prescribing opioids for pain in cancer 
versus non- cancer contexts, and acknowledgement that 
compassion and greater perceived community acceptance 
were driving factors, in addition to scientific support for 
mechanisms and clinical efficacy. Participant attitudes 
towards prescribing for people with cancer versus 
non- cancer pain differed most when cancer was in the 
palliative phase, when they were unconcerned by misuse. 
Participants were equivocal about the risk–benefit ratio of 
long- term opioid therapy in the chronic phase of cancer, 
and were reluctant to prescribe for disease- free survivors. 
Theme 3 (‘The question is always, ‘how lazy have you 
been?’) captured participants’ acknowledgement that 
they sometimes prescribed opioids for cancer pain as a 
default, easier option compared with more holistic pain 
management.
Conclusions Findings highlight the role of specific clinical 
considerations in distinguishing risk of opioid misuse in 
the cancer versus non- cancer population, rather than 
diagnosis per se. Further efforts are needed to ensure 
continuity of care where opioid prescribing is shared. 
Greater evidence is needed to guide opioid prescribing in 
disease- free survivors and the chronic phase of cancer, 
especially in the context of new treatments for metastatic 
disease.
IntrODuCtIOn
In the USA, a marked increase in prescribing 
opioids for chronic non- cancer pain and 
associated harms1 has been referred to as a 
‘crisis’,2 with many other high- income coun-
tries following a similar, though less exag-
gerated, trend.3–6 In Australia, for example, 
opioid dispensing episodes increased 15‐fold 
between 1992 and 2012, opioid‐related hospi-
talisations increased from 605 to 1464 cases 
(1998–2009) and the death rate due to acci-
dental poisoning increased from from 0.78 
to 1.19 deaths/100 000 population (2002–
2011).3 There has been a substantial body 
of research aimed at understanding factors 
underlying the opioid crisis and the best ways 
to address these in policy and practice.7 8
Drug misuse is defined as ‘the use of a 
substance for a purpose not consistent with 
strengths and limitations of this study
 ► This is the first study to explore the perspectives of 
Australian general practitioners (GPs) regarding the 
risk and context of opioid misuse in people with can-
cer and pain.
 ► Emerging themes were discussed with specialists in 
palliative medicine and oncology to identify avenues 
for exploration in subsequent GP interviews.
 ► GPs were purposively sampled to include those prac-
tising in regional as well as metropolitan Australia.
 ► Generalisability is likely to be reduced by the fact 
that participants were paid for time spent being in-
terviewed, were mostly from New South Wales and 
included some with specialty qualifications.
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legal or medical guidelines’.9 As such, it is partly defined 
by the clinical context in which a medication is prescribed. 
Compared with the non- cancer pain context, relatively 
little emphasis has been placed on opioid misuse in 
people with pain and cancer. Due to the greater number 
of people with chronic pain, a smaller overall volume 
of opioids is prescribed for the cancer population,5 and 
more evidence is available that opioids are effective in 
managing cancer10 than non- cancer11 pain. At least in the 
USA, people with cancer have also been less likely to die 
from opioids than other members of the general popula-
tion.12 Opioids are on WHO’s list of essential medicines, 
but access for people with cancer is already limited in 
many parts of the world—an alternative ‘crisis’ that sees 
millions suffer unnecessarily each year.13 14 Even in high- 
income countries, almost a third of people with cancer 
have unrelieved pain.15 There have been calls to ensure 
that policies aimed at reducing opioid misuse in the non- 
cancer pain context do not compromise access for people 
with cancer pain.16–21
A limited focus on risk of opioid misuse in the cancer 
pain context extends to the clinical as well as policy envi-
ronment. Cancer pain guidelines are primarily concerned 
with opioid- related problems relating to toxicity rather 
than misuse.22–25 Where addiction and dependence are 
considered, this is primarily in the context of educa-
tion to allay disproportionate fears among patients and 
providers that pose an important barrier to effective 
opioid therapy.26 Although newer US guidelines are 
increasingly concerned with screening for misuse,27 
screening tools have received only limited validation in 
the cancer context.28
What little research is available about physician beliefs 
and attitudes suggests that they are less concerned about 
misuse when prescribing opioids for cancer versus non- 
cancer pain, at least in the end of life context.29–31 Only 
two studies have directly compared physician perspec-
tives on cancer versus non- cancer pain,30 31 with results 
suggesting that key considerations may include the 
shorter duration of therapy towards the end of life, differ-
ences in therapeutic intent (maximum comfort vs opti-
mising function) and guidance from WHO Cancer Pain 
Ladder.32 A further study in the palliative care setting 
which included both patients with and without cancer 
found that concerns about misuse were primarily centred 
on inadvertent misuse (eg, repeating a dose due to cogni-
tive impairment) or diversion by families.33
At the same time, however, a growing number of 
voices have cautioned against complacency in the cancer 
context.27 34–41 A recent systematic review concluded that 
up to one in five people with cancer may be at risk of 
opioid misuse.42 Little is known about prescribing patterns 
and long- term effectiveness during the chronic phase or 
in disease- free survivors.27 34 38–40 43 The small number of 
studies available on disease- free survivors suggest that 
opioid prescribing may sometimes continue many years 
after treatment, with questionable benefit.44–46 There have 
also been concerns that surgical patients discharged from 
hospital may be overprescribed quick- release opioids to 
ensure adequate short- term pain management.41 Also, 
many people living with cancer pain have pain from 
other causes, such as treatment or comorbid conditions, 
for which opioids may be less effective.35 47 Finally, a 
smaller proportion of people living with cancer may have 
a history of misusing opioids or other substances prior 
to their diagnosis that may influence (but should not 
exclude) future opioid therapy.21 Currently, no evidence 
is available on how physicians consider these issues when 
balancing benefits against risks from opioids in the cancer 
pain context. Also, most research has focused on the US 
experience of the opioid crisis, with relatively little being 
conducted in other countries following a similar pattern 
of opioid overprescribing.
The current study aimed to explore the experiences, 
beliefs and attitudes of general practitioners (GPs) 
concerning the risk of opioid misuse in people with 
pain and cancer and related clinical considerations. We 
focused on GPs rather than oncology or palliative care 
specialists because of the greater potential afforded for 
examining how experiences, beliefs and attitudes might 
differ between cancer versus non- cancer pain and end of 
life versus chronic and disease- free contexts.
MethODs
A qualitative approach was considered best suited to 
exploring GP experiences, beliefs and attitudes and their 
relationship to clinical decision- making.48 A pragmatic 
integrative approach (ie, both deductive and induc-
tive49) was taken to balance the need for an exploratory 
approach warranted by the paucity of previous research 
on problematic use of opioids in the cancer context with 
the opportunity to build on findings from a large number 
of studies in the non- cancer pain context.30 31 33 50–62
The study was conducted between April 2018 and 
January 2019. All participants gave written informed 
consent to participate. The study has been reported in 
accordance with Consolidated Criteria for Reporting 
Qualitative Research.63
Patient and public involvement
The design of this project was informed by members of 
the Consumer Advisory Panel of the Improving Pallia-
tive, Aged and Chronic Care through Clinical Research 
and Translation Centre at the University of Technology 
Sydney, who attended an initial meeting to shape the 
research questions and draft the interview topic guide.
Participants
Eligible participants were GPs with experience of 
prescribing opioids to people with cancer and pain. GPs 
were recruited via email listservs and conferences/forums 
of GP organisations (eg, Royal Australian College of 
General Practitioners) and groups concerned with cancer 
and/or pain involving GPs among others (eg, the NSW 
Translational Cancer Research Centres). We also directly 
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approached GP practices in the researchers’ local state of 
New South Wales (NSW) via telephone and email. Prac-
tices were selected using a quasi- randomised approach 
using Google Maps, with practices stratified according to 
the Australian Bureau of Statistics remoteness structure64 
to purposively sample from metropolitan and regional 
areas. Sample size was determined by saturation of major 
themes against the conceptual framework used for anal-
ysis. Saturation was defined as no new themes emerging 
over five consecutive interviews.
Data collection
We conducted semistructured telephone interviews with 
participants over the telephone to capture a geographi-
cally diverse sample and enable a standardised approach 
regardless of location. Interviews were conducted by a 
single investigator (TL), a male allied health professional 
and social scientist with a doctoral degree and experience 
in qualitative methods. The interviewer had no relation-
ship with any of the GP participants prior to the inter-
views. Written and verbal information about the study 
identified that it was exploring similarities and differ-
ences between opioid- related problems in people with 
cancer versus non- cancer pain.
An initial question asked physicians ‘what (if any) prob-
lems have you encountered when prescribing opioids 
to people with cancer and pain?’ to elicit their perspec-
tives on the most common and/or important issues with 
minimal influence from the interviewer. Further ques-
tions explored a range of micro (patient, physician), 
meso (local practice) and macro (policy) factors found 
to influence physician perceptions of risk of misuse by 
previous research in the non- cancer pain context. These 
factors were located within a framework for prescription- 
related decision- making by Raisch,65 which divides influ-
ences into patient factors, prescriber and practice factors, 
and internal processing (including attitude towards the 
medication in question, perceived subjective norms and 
cognitive biases). Participants were asked to comment 
on the construct of ‘chemical coping’, which has been 
used in the cancer literature in various ways that approxi-
mate more or less to addiction.66 The interview guide was 
expanded as necessary to pursue additional points raised 
by interviewees and to test the authenticity of themes that 
emerged from previous interviews (see online supple-
mentary file). No field notes were taken.
GP interviews were audio recorded, transcribed and 
deidentified, and managed using NVivo V.11 (QSR) soft-
ware. Neither transcripts nor findings were not returned 
to participants for verification.
Analysis
Analysis of initial interviews followed a process of famil-
iarisation and line- by- line open coding against the 
framework outlined above, with codes added as needed 
to capture unanticipated insights.49 To enrich interpre-
tation as well as enable reflection on bias,67 analysis was 
conducted by two researchers independently who met 
afterwards to reach consensus around code applica-
tion—the interviewer (TL) and a female palliative care 
nurse with more limited qualitative research experience 
working as a research assistant (BR).
Emerging themes were explored via discussion with 
small number of senior specialists in palliative medicine 
(n=3) and doctors working in oncology (one medical 
oncologist, one radiation oncologist and one pain medi-
cine specialist working in a surgical oncology unit) among 
the authors’ networks. Specialist perspectives were not 
used as data; instead, they identified avenues for further 
exploration in subsequent GP interviews.
As analysis approached saturation, the initial stages of 
analysis were omitted, and the two researchers (TL and 
BR) independently coded against themes and then met 
to reach consensus. During this stage, the researchers 
searched for insights that might require the generation 
of new themes to accommodate them, as well as nuances 
in the established themes. Themes were further refined 
through discussion with members of the authorship team, 
including a psychologist specialising in pain manage-
ment (TN- J) and palliative care nurse (JP). No member 
checking was conducted with GPs.
results
Twenty- two GPs were interviewed. Of these, 12 were 
recruited through email listservs and conferences/
forums, and 10 were recruited through direct approaches 
to medical centres. Two hundred and twenty- one medical 
practices had to be approached to recruit these 10 partic-
ipants (each from a different medical centre). A response 
rate could not be estimated because the number of GPs at 
each medical centre was unknown. However, 10 medical 
centres represent less than 1% of the total 2731 in NSW.68 
Because direct approaches involved leaving messages 
with medical centre reception, no reasons could be ascer-
tained for GPs declining.
Interviews lasted a median of 31 min (IQR 29.75–
36.50). GP participants had a mean age of 53 (SD 11.06). 
See table 1 for other sample characteristics.
Three major themes emerged and are discussed next.
Misuse is not the main problem
When asked the initial question about what opioid- related 
problems they had encountered in the cancer context, 
nearly all participants referred to unrelieved pain, opioid 
toxicity or challenges in opioid selection and titration as 
being more pressing than risk of misuse. Opioid- related 
problems of all kinds were seen as arising, in large part, 
from systemic origins.
Poor continuity of care
Opioid- related misuse and other problems were 
perceived to arise most often from a lack of communi-
cation between prescribers, either cancer specialists 
and GPs, or two or more GPs. Lack of communication 
was primarily reported by participants in metropolitan 
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Table 1 Characteristics of general practitioners (GPs) 
participating in interviews about the risk and context of 




  NSW 18 (82)
  ACT 2 (9)
  QLD 1 (4)
  SA 1 (4)
Remoteness
  Metropolitan 13 (59)
  Regional 9 (41)
Also trained in other specialties
  No other specialty 16 (73)
  Addiction medicine 2 (9)
  Pain medicine 1 (4)
  Palliative care 1 (4)
  Forensic medicine 1 (4)
  Orthopaedics 1 (4)
Also work in other settings
  Primary care only 16 (73)
  Drug and alcohol 2 (9)
  Hospice 1 (4)
  General medical 3 (14)
  Conjoint academic appointment 2 (9)
Years practising as GP*
  < 5 years 2 (10)
  5–10 years 4 (20)
  11–20 years 5 (10)
  21–30 years 3 (15)
  > 30 years 6 (30)
How often, on average, have you initiated opioids for a 
patient with cancer pain over the past year?*
  Daily 0
  Daily to weekly 0
  Weekly to monthly 7 (35)
  Less frequently than monthly 11 (55)
  Not at all 2 (10)
How often, on average, would you see patients with 
cancer pain who have been prescribed opioids by another 
physician over the past year?*
  Daily 0
  Daily to weekly 2 (10)
  Weekly to monthly 7 (35)
  Less frequently than monthly 10 (50)
  Not at all 1 (5)
Continued
Characteristic N (%)
How often, on average, have you initiated opioids for a 
patient with non- cancer pain over the past year?*
  Daily 0
  Daily to weekly 0
  Weekly to monthly 8 (40)
  Less frequently than monthly 11 (55)
  Not at all 1 (5)
  Authorised methadone prescriber* 2 (10)
*Data missing for two GPs; percentages reflect N=20.
ACT, Australian Capital Territory; NSW, New South Wales; QLD, 
Queensland; SA, South Australia.
Table 1 Continued
areas, with rural participants enjoying clearer shared 
prescribing arrangements with their medical colleagues. 
Poor communication resulted in a lack of shared under-
standing about the goals and plan for opioid therapy, as 
well as limited knowledge transfer regarding important 
patient- level factors (eg, history of substance misuse). 
Most participants reported that discharge letters from 
cancer services often suffered lengthy delays and rarely if 
ever included information about opioid therapy, instead 
focusing on cancer treatment.
You get a discharge letter saying they've been sent 
home on it [the opioid]. And that’s all you get. They 
[the patient] get a list of their medication. Nobody 
ever gives you a plan for getting off it. (GP24, regional)
Many participants reported seeing patients who they 
suspected had been initiated on suboptimal opioid 
types and/or doses by another prescriber but lacked a 
complete medical history to interrogate this clinical deci-
sion. While participants would sometimes contact the 
initial prescriber to clarify, this was made more difficult 
where initiation was a long time ago or GPs lacked the 
confidence to question a prior decision, especially where 
this had been made by a specialist.
GP registrars, younger doctors, people are not so 
used to not being comfortable maybe thinking, “Well 
is this a situation where dare I interrupt specialist X 
and check with them?” Patient’s saying to me, “Oh 
they said I should be on this dose or this dose,” and 
there’s no written information. It’s about enabling 
other primary health care physicians to understand 
when it is appropriate to be a bit more assertive in 
terms of taking more responsibility for the commu-
nication process and not assuming that someone is 
going to ring you. (GP11, metropolitan, addiction 
specialist)
Many participants emphasised that opioid therapy was 
best undertaken within the context of an established ther-
apeutic relationship, especially where ‘difficult conver-
sations’ were required that involved either questioning 
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another prescriber’s decision or raising concerns about 
risk of misuse.
Sometime it’s very difficult for them [patients], as to 
counsel them “look, how about this? And just, can 
you try this little bit lower dose and we’ll see you in 
two weeks?” Sometimes they’re really reluctant to do 
that [but] we have a good relationship and do really 
well. (GP20, regional)
Sharing care between primary and specialist providers 
was seen as potentially disruptive to the doctor–patient 
relationship, reducing clarity about which prescriber was 
better placed to lead opioid therapy.
I think the patients become quite attached and feel 
quite secured to the [oncology] department, and I 
know in the past I’ve felt I’ve really lost touch with 
people. (GP17, regional)
Routine overprescribing on discharge from hospital
Participants voiced particular concern over what they saw 
as indiscriminate and often unnecessary prescribing of 
short acting, strong opioids on discharge from hospital, 
especially oxycodone. Such overprescribing on discharge 
was considered to be common regardless of whether pain 
occurred in cancer versus non- cancer context. Partic-
ipants reported illustrative cases where patients had 
continued to request short- acting opioids after postop-
erative pain had resolved and been resistant to weaning 
or switching to a long- acting opioid where pain was from 
residual disease.
A little factor is the hospitals dish out Endone [brand 
name for oxycodone] like it is a Smartie [brand name 
for a popular confectionary]. (GP12, metropolitan)
If someone is using regular Endone, I’m going to try 
and convert them to a longer acting opioid to try and 
manage it better. But people try and put up a—they 
are resistant to that. (GP15, regional)
Lack of prescriber expertise
Many participants perceived shortcomings in opioid- 
related expertise either in themselves or their colleagues. 
Education and training in opioid therapy were consid-
ered to be suboptimal both during medical training and 
post qualification.
I find it a little bit challenging sometimes to know 
when to stop or how to reduce the dose of the opioids 
… We had one or two lectures that talked about opi-
oids but, apart from that, it is from day to day when 
we see the patients that we learn more about our pre-
scriptions. (GP22, metropolitan)
Many participants reported illustrative cases where they 
perceived a colleague had made an inappropriate choice 
regarding opioid type or dose due to lack of expertise, 
resulting in either overprescribing or underprescribing.
When I took over, he [the patient] was already on 
80[mg] of oxycodone and a fentanyl patch, but the 
pain was not controlled. And within the last week or 
so, when the doctor seen him, he told him categori-
cally, “oh, you're on the highest dose—we cannot give 
you anything more.” He had a red line of thinking of, 
“this is my maximum dose—I’m not going to give you 
anything more.” (GP20, regional)
Several participants also highlighted the limited oppor-
tunity that their primary care caseload afforded them to 
develop expertise in opioid therapy.
Because we don’t do [opioid therapy] very often … 
I used to work in the palliative care team [and at] 
that time I was really good at calculation … we need 
to just revise notes again and it takes time. (GP26, 
metropolitan)
Primary care constraints
Many participants emphasised the time required to 
engage in high- quality, person- centred pain management 
and how this was constrained by the business model of 
contemporary primary care. Participants also highlighted 
constraints on titrating opioids in the primary care versus 
inpatient setting due to the more limited opportunity for 
rapid review.
If we prescribe opioids for pain, it’s good to follow up 
within 24 to 48 hours to make sure we’ve got the dose 
right. But in general practice, that’s often difficult. 
(GP21, regional)
Lack of alternatives to strong opioids for safe, effective pain relief
Several participants reported the lack of alternatives to 
strong opioids for effectively managing cancer pain. While 
useful for some patients, non- pharmacological strategies 
were considered to be limited in addressing severe cancer 
pain and to make high demands on patients’ time, effort 
and finances, especially where allied health referral was 
required.
They [allied health referrals for non- pharmacological 
management) still have their limitations in terms of 
number of sessions, in terms of location of where 
they are, in terms of whether your knowledge of the 
therapists and whether they’re any good or not (you 
don’t want to send anyone to just any old person). So 
there’s all these limitations—system limitations, your 
own limitations. Sometimes limitations that the pa-
tient might put on it too, that they just don’t want to 
go to that effort, to that time; they want a quick fix. 
(GP11, metropolitan, addiction specialist)
Partial agonists (eg, tramadol) were highlighted by one 
participant as being effective alternatives to full agonist 
opioids that were associated with a lower risk of misuse. 
Limited uptake of partial agonists was blamed partly on 
aggressive marketing from the pharmaceutical industry 
of opioids of other kinds, most notably oxycodone.
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While often used in conjunction with opioids, non- 
opioid medications were considered to have limited effec-
tiveness for some cancer pain, and also to confer different 
problems of their own.
Drugs like pregabalin, yeah they help a bit for cer-
tain types of pain. Amitriptyline is a useful adjunct. 
But take away the opioids, there’s not a real lot left. 
(GP21, regional)
‘A different mindset’ for cancer pain
Participants generally reported aberrant behaviours (eg, 
‘doctor shopping’) to be rarer in patients with cancer 
versus non- cancer pain. However, nearly all had encoun-
tered at least some patients with cancer where these 
behaviours had been of concern.
Opioids are more effective for cancer pain
Several participants referred to research evidence and 
experience indicating opioid therapy to be more effec-
tive for cancer versus non- cancer pain. Some suggested 
that opioids for cancer versus chronic non- cancer pain 
could be more targeted to specific underlying causes, and 
delineated effectiveness for different types of cancer pain, 
most notably nociceptive versus neurological.
I think, well, it’s all just pain [both cancer and non- 
cancer], but I do tend to see probably more people 
who are hard to budge who have chronic back pain 
or chronic musculoskeletal stuff, more than cancer 
pain. (GP28, metropolitan)
In cancer pain, sometimes we’ve actually gotten more 
up our sleeves than in our more functional pain syn-
dromes because often you’ve got anatomical prob-
lems. You’ve got really cellular pathological issues 
that you could put a finger on more easily than, for 
example, something like fibromyalgia or essential 
pain processing disorder … some of the other chron-
ic pain syndromes, we’re saying, “we have no idea 
why everything hurts all the time, but here’s a drug.” 
… [in cancer pain] we can do these various things 
with these various terminologies that we can really 
nail down management to. And in that context, use 
of opioids becomes very specific, if you know what I 
mean? (GP23, metropolitan)
The difference with the cancer pain as opposed 
to some of the other pains, is that there is some-
thing actually going on, whereas sometimes with 
these pain syndromes where people have just got 
sore backs all the time and musculoskeletal pain, 
the actual benefit to the pain can be vaguer. (GP28, 
metropolitan)
At the same time, there was widespread recognition 
among participants that patients with cancer might 
present with pain from comorbidities rather than or as 
well as their tumour, sometimes predating their diagnosis.
Opioids have reduced stigma in the cancer pain context
Several participants expressed a belief that the community 
showed greater acceptance of opioids as an appropriate 
medication for managing cancer versus non- cancer pain. 
Some participants expressed concern that, in the non- 
cancer pain context, media attention and monitoring in 
response to the opioid crisis had led to stigmatisation of 
patients and a growing reluctance among many GPs to 
prescribe, even when opioids were indicated. By compar-
ison, people with cancer pain were considered unlikely to 
suffer poor pain control as a result of these factors.
They’re not the people who will miss out because 
cancer patients are easy for me to justify [prescrib-
ing opioids to]. (GP32, metropolitan, orthopaedic 
specialist)
Differences in misuse-related concerns are dependent on cancer 
stage
Misuse- related concerns appeared to rest more on 
prognosis than diagnosis; misuse was considered of low 
priority in managing both cancer and non- cancer pain 
where prognosis was poor, due to the shorter duration 
of therapy and the focus on maintaining comfort rather 
than functioning. In this context, all participants indi-
cated they were willing to prescribe as liberally as was 
required to manage pain.
If it’s palliative, definitely, we don’t really worry about 
if he gets addicted. (GP20, regional)
Interviewer: would you be thinking in similar terms 
between somebody with cancer and somebody with a 
non- malignant condition if their life expectancy was 
similar—that would be a critical element for you?
GP10: Yeah—I think that makes a difference because 
obviously the questions in long term addiction and 
dependency are different than [for] somebody who 
will not live very long. (GP10, metropolitan)
In the palliative context, reluctance to take opioids (on 
the part of patients) or prescribe opioids (on the part of 
doctors) were considered to be of greater concern than 
the risk of misuse.
They don’t want morphine, because morphine 
equals death … we have to convince people to have 
opioids in the hospice. Because we know they’ve got 
pain, and they’re terrified of having the opioids. So 
[misuse] that’s never seen, and I’ve worked there for 
years. (GP12, metropolitan, forensic specialist)
Somebody not being given the dose of oxycodone 
that they need … and this is someone who’s in the 
last, probably, two or three months of life. To me, it’s 
just—it’s ludicrousness, and I am someone who is 
very cautious in terms of prescribing drugs of addic-
tion. (GP13, metropolitan)
Participants expressed only one concern specific to the 
palliative context, namely that patients might stockpile 
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opioids as a recourse for ending their own life if suffering 
became unbearable.
I’ve had an instance where there’s been hoarding go-
ing on in case they’ve had enough one day and they 
just take the whole lot in one go. (GP30, metropoli-
tan, pain specialist)
Participants were much more concerned about risk of 
misuse in disease- free cancer survivors, who were gener-
ally regarded as being no different to people with non- 
cancer pain. Several participants reported that patients 
with early stage disease were often keen to stop opioid 
therapy because of its association with being ill.
I think that [weaning] would also tie in with their 
belief that they’re putting things behind them and 
moving forward. (GP17, regional, palliative care 
specialist)
However, a few participants cited examples of patients 
who were slow to weaned off opioids following curative 
treatment, including one who took 2 years.
I can think [of] two people off the top of my head at 
the moment where there’s been diagnosis of cancer, 
they’ve been treated with opioids, gone into remis-
sion, and then their opioids become an issue. One of 
the people that I’m thinking about who … [had] lots 
of pain, high dose opioids, probably on about, I don’t 
know, 300 of morphine equivalents a day, and then 
went into remission and then found it really hard to 
cut down. And he was really committed to stopping. 
But it was really hard for him to stop. Needed lots of 
support. We did it over a two year period where he cut 
down and ceased completely. And that was with some-
one who was really committed and had a partner who 
was really supportive. (GP13, metropolitan)
The chronic phase of advanced cancer was consid-
ered by participants to occupy middle and more equiv-
ocal ground between the palliative phase and early 
stage disease when weighing up opioid- related risks 
versus benefits. Participants reported finding this phase 
especially challenging because patients had pain that 
required opioid analgesia but duration of therapy could 
be extended and uncertain.
The shorter prognosis is definitely much easier 
and so, if the patient hasn’t seen palliative care and 
they’ve got cancer and they may live for a long time, 
it makes our lives a tiny bit more difficult because 
there’s all these articles being published about how 
bad GPs are and the specialists are prescribing S8’s 
for patients which should be short- term only, they 
must be more aware because everybody gets hooked 
on their S8’s [Australian classification for drugs of ad-
diction] … often what we do after a long time is the 
patient seems to have no pain, is sometimes try and 
decrease their dose. But one’s got the dilemma if you 
decrease the dose and the patient starts getting more 
pain then people gonna ask you, “Doc, if the patient 
was stable why did you make him uncomfortable?” 
(GP25, metropolitan)
The role of cognitive bias
Several participants reflected on the possibility that 
prescribers could be ‘blinded’ to the risk of opioid misuse 
in people with advanced cancer due to their feelings of 
compassion and focus on relieving suffering. Cognitive 
bias of this kind was perceived both to make prescribers 
more willing to prescribe at high dose and frequency, and 
also to be associated with reduced monitoring of warning 
signs related to misuse.
That person was taking from the same prescription 
of fentanyl patches from two different doctors for the 
last six months … We always have a soft heart for the 
cancer patients as well, like, we don’t really go into 
their details—so that’s what happened [in this case]. 
(GP20, regional)
Having the opioid conversation with anyone is a hard 
conversation because no one likes to be told to re-
duce the medication that they think helps their pain 
… it’s even harder to have the difficult conversation 
with someone who has a shortened life expectancy. 
(GP15, regional)
You know—it’s the big C, it’s soul- consuming. It’s so 
terrible that this is happening to my patient, I gotta 
get them some extra opioids to make sure they’re 
okay. So, there’s a bit of a different mindset, I think. 
(GP13, metropolitan)
Chemical coping
Not all participants were familiar with the construct of 
chemical coping, and those who were brought varying 
interpretations. For two participants, chemical coping 
served as a ‘softer’ synonym for addiction in people 
with advanced cancer that avoided conferring stigma 
to people who were unwell. For another, however, it 
differed from addiction in stemming from a fear of 
pain rather than dependence on opioids. On this view, 
chemical coping could be addressed by reassuring 
patients that the pain would not return if opioids were 
reduced or by substituting opioids with other forms of 
pain control.
I think the ‘chemical coper’ is a really nice term. It’s 
a bit of a softer way of talking about someone who’s 
actually using medicines to manage their complex 
life, I guess. But because they’ve got a legitimate con-
dition, they’re called a ‘chemical coper’ rather than 
someone who’s running around the streets grabbing 
Oxycontin and injecting. (GP13, metropolitan)
I don’t view it as addiction, which I see as more of a 
physiological phenomenon rather than a psycholog-
ical one. (GP21, regional)
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Risk of diversion
Diversion was considered to be of greater concern than 
misuse by patients, either through the patient intention-
ally procuring opioids in order to give or sell to others, 
or through family/friends diverting opioids without the 
patient’s consent.
It’s a very common story … obtaining opioids from 
family members … If you’re in Sydney on the min-
imum wage … oxycodone is a dollar a milligram on 
the streets (GP13, metropolitan)
Although participants reported diversion also to be 
common in non- cancer contexts, a small number worried 
that people with cancer might be used as a ‘gateway’ for 
opioids because of prescribers’ greater willingness to 
initiate opioids for cancer pain.
‘the question is always, ‘how lazy have you been?’’
A recurring theme among interviews was that opioid- 
related problems most commonly arose when pain 
management lacked a comprehensive assessment, shared 
decision- making and communication among members of 
the care team. Several participants highlighted how much 
easier and less time consuming it was to prescribe opioids 
than to explore more holistic approaches to pain control 
based on a comprehensive assessment, partnering with 
patients and involving a multidisciplinary team.
The question is always, “how lazy have you been?” You 
know, I saw this in the country all the time, that it 
is so much simpler to write doses, you know, 80 mg 
Oxycontin b.d. … than it is to get people involved in 
multi- disciplinary team. (GP23, metropolitan)
For a GP out there in the community, it’s quick and 
easy to write a script, be that for whatever. When it 
comes to pain patients, they need a lot more support, 
because I’ll have to actually look first at the psychoso-
cial aspects, because I presume with the cancer diag-
nosis, the bio part of that biopsychosocial model has 
already been elucidated … opioids can be helpful, 
but it can also be a hindrance. (GP30, metropolitan)
Demands on time and effort were reported to be 
even greater where prescribing was shared between two 
or more doctors. In these instances, participants high-
lighted the need to maintain regular communication 
between prescribers to clarify roles and the management 
plan. There was also an emphasis on the need for each 
prescriber to independently review pain management 
plans rather than defer responsibility to the initiating 
doctor.
It was always important to be in close contact with the 
oncologist and if there was a palliative care team in-
volved to be crystal clear about that we were working 
together we all need to know what each other’s doing 
and we need to have our roles very clearly defined 
in terms of who is the person who is managing the 
analgesia. (GP11, metropolitan, addiction specialist)
Every time you’re thinking about writing a script, you 
are responsible for that script … even if the oncol-
ogist said, “Oh, yes I would give them this.” They 
haven’t written a script—you are legally responsible 
for the script. And so, you need to make an assess-
ment and satisfy yourself that this is an appropriate, 
safe treatment. (GP13, metropolitan)
DIsCussIOn
This is the first study to explore the perspectives of 
Australian GPs on the risk of opioid misuse in people 
with cancer versus non- cancer pain and related clinical 
considerations. Consistent with studies from the UK and 
USA,30 31 participants were less concerned about misuse 
in the end of life context, due to a likely shorter dura-
tion of therapy and priority afforded pain control. Partici-
pants were less at ease with opioid therapy for cancer pain 
where duration of therapy and prognosis were uncertain. 
Participants viewed risk of misuse as arising substan-
tially from systemic and prescriber limitations, including 
shortcomings in continuity of care and prescriber exper-
tise and the demands on time/effort required for safe, 
holistic pain management.
Our results lend support to concerns that opioids 
may sometimes be overprescribed in the cancer context 
because doctors feel an imperative to help and perceive 
there to be few management alternatives.37 Our findings 
suggest that compassion towards patients with cancer may 
sometimes cause GPs to be slower to associate opioid- 
related behaviours with misuse or addiction in favour of 
softer constructs like ‘chemical coping’. Participants in 
our study admitted being less alert to risk of misuse in 
people with cancer versus non- cancer pain, consistent 
with a survey study that found pain specialists to be less 
likely to screen for misuse in this population.69 While 
participants reported encountering misuse less often in 
cancer versus non- cancer pain contexts, this might, in 
part, have been due to lower case identification. This is 
consistent with a systematic review which found studies 
using subjective methods underestimated risk of misuse 
in people with cancer compared with objective methods.42 
Participants’ emphasis on the goal of comfort care as a 
justification for liberally prescribing opioids towards the 
end of life should also be interpreted within the context 
of research suggesting that doctors sometimes overesti-
mate patients’ desire to be pain free at the expense of 
mental clarity.70 GPs in our study also seemed to have 
lower levels of concern regarding addiction and misuse 
in the palliative context than has been reported for palli-
ative care physicians.71
Our study is also consistent with limited evidence that 
opioid prescribing may sometimes continue longer than 
is optimal for disease- free survivors.34 37 44 45 Canadian and 
Norwegian studies of population- based data found opioid 
use to be higher in cancer survivors than the general 
population even 5 or 10 years after diagnosis.44 46 A third 
or more of Norwegian cancer survivors taking opioids 
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were prescribed short- acting only, consistent with partic-
ipant perceptions in the current study that weaning or 
transitioning to long- acting opioids from short acting is 
sometimes challenging. Participants commonly expressed 
a concern that short- acting opioids are overprescribed on 
discharge from hospital—a concern that has prompted 
recent Australian research aimed at reducing oxycodone 
prescribing in this setting.72 Guidelines for managing 
pain in long- term cancer survivors recommend that initi-
ating opioid therapy should be treated with the same 
caution as in the non- cancer pain context—that is, only 
trialled where other options have failed and accompa-
nied by proactive efforts to taper and cease and minimise 
risk of addiction and misuse.27 More guidance is needed 
for pain management in the early months of disease- 
free survivorship.27 In the meantime, our results suggest 
that helping survivors see tapering opioids as a means of 
‘moving on’ from their cancer experience more generally 
may support the transition for some patients.
GPs in our study also faced a dilemma in deciding 
when to trial weaning of opioids in people during the 
chronic phase of cancer. Limited evidence and guidance 
are available to inform opioid therapy in this population. 
Prescribing for this group may be even more complex in 
the context of emerging cancer treatments,34–37 which 
lengthen the chronic phase of advanced disease and 
increase prognostic uncertainty for some tumour types.
In addition to worrying less about misuse in the context 
of poor prognosis, participants’ relative comfort with 
prescribing opioids in the palliative versus disease- free or 
chronic cancer phases related to confidence in the mech-
anisms by which pain was being caused and that opioids 
might work. Confidence that a patient was experiencing 
pain as a result of cancer faced further challenges in 
the context of comorbidities that might be causing pain 
or when addiction or the similar construct of chemical 
coping was suspected.
Poor continuity of care has long been identified as a 
barrier to pain control for people with cancer.73 However, 
our study is the first to elucidate its potential to contribute 
to opioid misuse in this population. Addressing this 
problem may require standardised processes for commu-
nication that go beyond discharge letters and are 
embedded within systems as non- discretionary. Elec-
tronic health records pose special potential for enabling 
communication of this kind but have been slow to over-
come privacy concerns and structural barriers between 
primary and acute care in Australia.74
Participant perceptions that opioid use by patients 
with cancer versus non- cancer is relatively free of stigma 
contrasts with findings from a US study that people with 
cancer face similar attitudinal barriers as patients with 
non- cancer pain, resulting in undertreatment.75 The 
opioid crisis is more severe in the USA, with propor-
tionate government and media attention. However, given 
increasing attention on opioid prescribing in the Austra-
lian context, policy may need to be proactive to avoid 
access barriers for people with cancer in the future.19
Finally, participants perceived that partial agonists (eg, 
tramadol) might pose less risk of misuse. However, recent 
evidence suggests that this difference may have been 
overestimated.76
limitations
Our results are unlikely to represent the perspectives of 
Australian GPs in general. Most participants worked in 
NSW, limiting insights into jurisdictional variation. Direct 
approaches to medical centres were intended to reduce 
the volunteer effect and ensure inclusion of regional as 
well as metropolitan GPs. However, we had a very low 
response rate from this sampling method. It seems likely 
that the controversial nature of the topic and reimburse-
ment offered for GP time may have attracted GPs with 
stronger held views and lighter patient caseloads than the 
population from which they were sampled. Inclusion of 
four GPs with specialty training in addiction medicine, 
pain medicine or palliative care, and two with conjoint 
academic appointments is indicative of a greater than 
average interest in opioid- related practice and research. 
Finally, having interviews conducted by a social scientist 
rather than a doctor may have meant some avenues of 
enquiry were missed, while at the same time posing less 
risk of confirmation bias compared with an interviewer 
with prescribing experience.
COnClusIOn
The current study suggests that misuse may not be the 
most pressing concern for GPs prescribing opioids to 
people with cancer, and highlights the role of specific 
clinical considerations in distinguishing risk of misuse for 
pain in the cancer versus non- cancer population, rather 
than diagnosis per se. Further efforts are needed to 
ensure continuity of care where doctors share prescribing 
for a given patient, especially between primary and acute 
care settings. Greater evidence is needed to guide opioid 
prescribing in disease- free survival and the chronic phase 
of advanced cancer, especially in the context of new 
targeted treatments for metastatic disease that lead to 
greater uncertainty regarding prognosis.
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